Bipolar I Disorder, Manic Or Mixed Episodes Therapeutics
1. Abilify patent expiration
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(3 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(11 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 years ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(3 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 1 month from now) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(4 years ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(3 years ago) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(6 months from now) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(4 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(5 years ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US6977257 (Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(3 years ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 6 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 23 days ago) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING; INJECTABLE; SOLUTION
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
